Medications in pregnancy and lactation: Part 1. teratology

Obstetrics and Gynecology

Volumn 113, Issue 1, 2009, Pages 166-188

  Buhimschi, Catalin S ^a   Weiner, Carl P ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CARBAMAZEPINE; CARBIMAZOLE; CYCLOPHOSPHAMIDE; DANAZOL; DIAZEPAM; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUCONAZOLE; IBUPROFEN; INDOMETACIN; ISOTRETINOIN; LISINOPRIL; LITHIUM; METHOTREXATE; MISOPROSTOL; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PENICILLAMINE; PHENYTOIN; RADIOACTIVE IODINE; SERTRALINE; SODIUM IODIDE 128; TERATOGENIC AGENT; THALIDOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; WARFARIN; DRUG;

BREAST FEEDING; CASE CONTROL STUDY; CONGENITAL MALFORMATION; DRUG LABELING; FETUS MALFORMATION; GASTROSCHISIS; GESTATION PERIOD; HUMAN; HUMAN DEVELOPMENT; KIDNEY FAILURE; LACTATION; PREGNANCY; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY; BREAST MILK; CHEMISTRY; FEMALE;

ABNORMALITIES, DRUG-INDUCED; BREAST FEEDING; FEMALE; HUMANS; MILK, HUMAN; PHARMACEUTICAL PREPARATIONS; PREGNANCY; TERATOGENS;

EID: 60749120688     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31818d6788     Document Type: Review

References (127)

1. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation. In: Queenan JT, Spong CY, Lockwood CJ, editors. Management of high-risk pregnancy: an evidence-based approach. 5th ed. Malden (MA): Blackwell Publishing Ltd; 2007. p. 38-58.
2. Carney EW, Scialli AR, Watson RE, DeSesso JM. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Birth Defects Res C Embryo Today 2004;72:345-60.
3. Giroux M, Teixera MG, Dumas JC, Desprats R, Grandjean H, Houin G. Influence of maternal blood flow on the placental transfer of three opioids-fentanyl, alfentanil, sufentanil. Biol Neonate 1997;72:133-41.
4. Shepard TH, Lemire RJ. Catalog of teratogenic agents. 12th ed. Baltimore (MD): John Hopkins University Press; 2007.
5. Clayton-Smith J, Donnai D. Human malformations. In: Rimoin DL, Connor JM, Pyeritz RE, editors. Emery and Rimoin's principles and practice of medical genetics. 3rd ed. New York (NY): Churchill Livingstone; 1997. p. 383-94.
6. Cabrera RM, Hill DS, Etheredge AJ, Finnell RH. Investigations into the etiology of neural tube defects. Birth Defects Res C Embryo Today 2004;72:330-44.
7. Steffensen FH, Nielsen GL, Sørensen HT, Olesen C, Olsen J. Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet 1998;351:596.
8. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51.
9. Mitchell AA. Systematic identification of drugs that cause birth defects-a new opportunity. N Engl J Med 2003;349: 2556-9.
10. Kennedy DL, Uhl K, Kweder SL. Pregnancy exposure registries. Drug Saf 2004;27:215-28.
11. Slone D, Shapiro S, Miettinen OS. Case-control surveillance of serious illnesses attributable to ambulatory drug use. In: Colombo, F, Shapiro S, Slone D, Tognoni G, editors. Epidemiological evaluation of drugs. Amsterdam (the Netherlands): Elsevier/North Holland Biomedical Press; 1977. p. 59-70.
12. Buhimschi CS. Endocrinology of lactation. Obstet Gynecol Clin North Am 2004;31:963-79.
13. Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med 2005;10:149-59.
14. Weiner CP. Introduction. In: Weiner CP, Buhimschi C, editors. Drugs for pregnant and lactating women. New York (NY): Churchill Livingston; 2004. p. XII-XV.
15. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health (Larchmt) 2005;14:104-9.
16. McNamara PJ, Abbassi M. Neonatal exposure to drugs in breast milk. Pharm Res 2004;21:555-66.
17. Solomon GM, Weiss PM. Chemical contaminants in breast milk: time trends and regional variability. Environ Health Perspect 2002;110:A339-47.
18. Dórea JG. Exposure to mercury during the first six months via human milk and vaccines: modifying risk factors. Am J Perinatol 2007;24:387-400.
19. Stowe ZN. The use of mood stabilizers during breastfeeding. J Clin Psychiatry 2007;68 suppl:22-8.
20. Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. J Psychopharmacol 1999;13:64-80.
21. Stultz EE, Stokes JL, Shaffer ML, Paul IM, Berlin CM. Extent of medication use in breastfeeding women. Breastfeed Med 2007;2:145-51.
22. Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs. Drug Saf 2002;25:885-92.
23. Wen SW, Yang T, Krewski D, Yang Q, Nimrod C, Garner P, et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol 2008; 28:324-9.
24. Tomlinson AJ, Campbell J, Walker JJ, Morgan C. Malignant primary hypertension in pregnancy treated with lisinopril. Ann Pharmacother 2000;34:180-2.
25. August P, Mueller FB, Sealey JE, Edersheim TG. Role of renin-angiotensin system in blood pressure regulation in pregnancy. Lancet 1995;345:896-7.
26. Easterling TR, Carr DB, Davis C, Diederichs C, Brateng DA, Schmucker B. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol 2000;96:956-61.
27. Landon MB. Diabetic nephropathy and pregnancy. Clin Obstet Gynecol 2007;50:998-1006.
28. Tabacova SA, Kimmel CA. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review. Reprod Toxicol 2001;15:467-78.
29. Miller RK, Jessee L, Barrish A, Gilbert J, Manson JM. Pharmacokinetic studies of enalaprilat in the in vitro perfused human placental lobule system. Teratology 1998;58:76-81.
30. Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol 1998;38:306-11.
31. Centers for Disease Control and Prevention (CDC). Postmar-keting surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep 1997;46:240-2.
32. Maliheh K, Abdorrazagh K, Armen K, Reza S. Angiotensin converting enzyme inhibitors and aortic arch obstructive malformations. Indian J Med Sci 2006;60:417-20.
33. Boix E, Zapater P, Picó A, Moreno O. Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 2005;28:1029-31.
34. Redman CW, Kelly JG, Cooper WD. The excretion of enalapril and enalaprilat in human breast milk. Eur J Clin Pharmacol 1990;38:99.
35. Devlin RG, Fleiss PM. Captopril in human blood and breast milk. J Clin Pharmacol 1981;21:110-3.
36. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 354: Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2006;108:1601-3.
37. ACOG Committee on Practice Bulletins - Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008;111:1001-20.
38. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antide-pressant treatment [published erratum appears in JAMA 2006;296:170]. JAMA 2006;295:499-507.
39. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003;73:330-7.
40. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:961-6.
41. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96.
42. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-7.
43. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-6.
44. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92.
45. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87.
46. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
47. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32.
48. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-75.
49. Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003;64:73-80.
50. Howard LM, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of postnatal depression. The Cochrane Database of Systematic Reviews 2005, Issue 2.Art. No.: CD004363. DOI: 10.1002/14651858.CD004363.
51. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
52. Hallberg P, Odlind V, Sjöblom V. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:2188-90.
53. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV.. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163-6.
54. Back DJ, Bates M, Bowden A, Breckenridge AM, Hall MJ, Jones H, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980;22:495-503.
55. Crawford P, Chadwick D, Cleland P, Tjia J, Cowie A, Back DJ, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:23-9.
56. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263-72.
57. Kjaer D, Horvath-Puhó E, Christensen J, Vestergaard M, Czeizel AE, Sørensen HT, et al. Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. BJOG 2008;115:98-103.
58. Azarbayjani F, Danielsson BR. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia 2002;43:457-68.
59. Jäger-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108:997-1004.
60. Nakamura H, Ushigome F, Koyabu N, Satoh S, Tsukimori K, Nakano H, et al. Proton gradient-dependent transport of valproic acid in human placental brush-border membrane vesicles. Pharm Res 2002;19:154-61.
61. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neuraltube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42 suppl:111-8.
62. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001;98:168-75.
63. Witters I, Van Assche F, Fryns JP. Nuchal edema as the first sign of fetal valproate syndrome. Prenat Diagn 2002;22:834-5.
64. Chaudron LH. When and how to use mood stabilizers during breastfeeding. Prim Care Update Ob Gyns 2000;7:113-7.
65. Pynnönen S, Kanto J, Sillanpää Erkkola R. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol (Copenh) 1977;41:244-53.
66. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17.
67. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000;37:489-97.
68. Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990;150:136-8.
69. McAuley JW, Anderson GD. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 2002;41:559-79.
70. Leppik IE, Rask CA. Pharmacokinetics of antiepileptic drugs during pregnancy. Semin Neurol 1988;8:240-6.
71. Webster WS, Howe AM, Abela D, Oakes DJ. The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des 2006;12:1431-48.
72. Iqbal MM, Sohhan T, Mahmud SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol 2001;39:381-92.
73. Shimoyama R, Ohkubo T, Sugawara K, Ogasawara T, Ozaki T, Kagiya A, et al. Monitoring of phenytoin in human breast milk, maternal plasma and cord blood plasma by solid-phase extraction and liquid chromatography. J Pharm Biomed Anal 1998;17: 863-9.
74. Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: safety considerations. Drug Saf 2005;28:695-706.
75. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005;65:185-8.
76. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs 2007;67:2727-46.
77. Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007;48:1207-10.
78. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication [published erratum appears in Arch Gen Psychiatry 2005;62: 768]. Arch Gen Psychiatry 2005;62:593-602.
79. American College of Obstetrics and Gynecology. ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy. Obstet Gynecol 2004;103:803-14.
80. Belfort MA, Anthony J, Saade GR. Prevention of eclampsia. Semin Perinatol 1999;23:65-78.
81. Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art No.: CD002960. DOI: 10.1002/ 14651858.CD002960.
82. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art No.: CD000127. DOI: 10.1002/14651858.CD000127.
83. Rosenberg L, Mitchell AA, Parsells JL, Pashayan H, Louik C, Shapiro S. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983;309:1282-5.
84. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002;101:147-54.
85. Kanto J, Erkkola R. The feto-maternal distribution of diazepam in early human pregnancy. Ann Chir Gynaecol Fenn 1974;63:489-91.
86. Gonzalez de Dios J, Moya-Benavent M, Carratala-Marco F. "Floppy infant" syndrome in twins secondary to the use of benzodiazepines during pregnancy [in Spanish]. Rev Neurol 1999;29:121-3.
87. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994;8:461-75.
88. Kart Koseoglu H, Yucel AE, Kunefeci G, Ozdemir FN, Duran H. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001;10:818-20.
89. Ozalp SS, Yalcin OT, Tanir HM. A hospital-based multicentric study results on gestational trophoblastic disease management status in a developing country. Eur J Gynaecol Oncol 2001;22:221-2.
90. Peters BG, Bray JJ, Masidonski P, Mahon SM. Issues surrounding adjuvant chemotherapy for breast cancer during pregnancy. Oncol Nurs Forum 2001;28:639-42.
91. Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999;86:237-41.
92. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001;16:632-7.
93. Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, Rosa R, Graziadio C. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 2005;73:634-7.
94. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 1992;28:148-52.
95. Amato D, Niblett JS. Neutropenia from cyclophosphamide in breast milk. Med J Aust 1977;1:383-4.
96. Duck SC, Katayama KP. Danazol may cause female pseudohermaphroditism. Fertil Steril 1981;35:230-1.
97. Minh HN, Belaisch J, Smadja A. Female pseudohermaphro-ditism [in French]. Presse Med 1993;22:1735-40.
98. Hammond MG, Hammond CB, Parker RT. Conservative treatment of endometriosis externa: the effects of methyltestosterone therapy. Fertil Steril 1978;29:651-4.
99. Grote K, Stahlschmidt B, Talsness CE, Gericke C, Appel KE, Chahoud I. Effects of organotin compounds on pubertal male rats. Toxicology 2004;202:145-58.
100. Baheiraei A, Ardsetani N, Ghazizadeh S. Effects of progestogen-only contraceptives on breast-feeding and infant growth. Int J Gynaecol Obstet 2001;74:203-5.
101. Ratchanon S, Taneepanichskul S. Depot medroxyprogester-one acetate and basal serum prolactin levels in lactating women. Obstet Gynecol 2000;96:926-8.
102. Bianchi S, Busacca M, Agnoli B, Candiani M, Calia C, Vignali M. Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Hum Reprod 1999;14:1335-7.
103. Kingsbury AC. Danazol and fetal masculinization: a warning. Med J Aust 1985;143:410-1.
104. Rosa FW. Virilization of the female fetus with maternal danazol exposure. Am J Obstet Gynecol 1984;149:99-100.
105. Kaya H, Babar Y, Ozmen S, Ozkaya O, Karci M, Aydin AR, et al. Intratubal methotrexate for prevention of persistent ectopic pregnancy after salpingotomy. J Am Assoc Gynecol Laparosc 2002;9:464-7.
106. Kulier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. Medical methods for first trimester abortion. The Cochrane Database of Systematic Reviews 2004, Issue 2. Art No.: CD002855. DOI: 10.1002/14651858.CD002855.
107. Creinin MD, Wiebe E, Gold M. Methotrexate and misoprostol for early abortion in adolescent women. J Pediatr Adolesc Gynecol 1999;12:71-7.
108. Gracia CR, Brown HA, Barnhart KT. Prophylactic methotrexate after linear salpingostomy: a decision analysis. Fertil Steril 2001;76:1191-5.
109. Dilbaz S, Caliskan E, Dilbaz B, Degirmenci O, Haberal A. Predictors of methotrexate treatment failure in ectopic pregnancy. J Reprod Med 2006;51:87-93.
110. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005;105:1203-5.
111. Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 1999;60:10-2.
112. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005;105:1203-5.
113. Sorosky JI, Sood AK, Buekers TE. The use of chemotherapeutic agents during pregnancy. Obstet Gynecol Clin North Am 1997;24:591-9.
114. Mestman JH. Diagnosis and management of maternal and fetal thyroid disorders. Curr Opin Obstet Gynecol 1999;11:167-75.
115. American College of Obstetrics and Gynecology. ACOG practice bulletin. Thyroid disease in pregnancy. Number 37, August 2002. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 2002;79:171-80.
116. Nachum Z, Rakover Y, Weiner E, Shalev E. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. Am J Obstet Gynecol 2003;189:159-65.
117. Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, et al. Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 2005;90:6093-8.
118. Azizi F, Bahrainian M, Khamseh ME, Khoshniat M. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J Pediatr Endocrinol Metab 2003;16:1239-43.
119. Shepard TH, Brent RL, Friedman JM, Jones KL, Miller RK, Moore CA, et al. Update on new developments in the study of human teratogens. Teratology 2002;65:153-61.
120. Nakamura S, Nishikawa T, Isaji M, Ishimori M, Shimizu N, Iwamura M, et al. Aplasia cutis congenita and skull defects after exposure to methimazole in utero. Intern Med 2005;44:1202-3.
121. Karg E, Bereg E, Gaspar L, Katona M, Turi S. Aplasia cutis congenita after methimazole exposure in utero. Pediatr Dermatol 2004;21:491-4.
122. Chattaway JM, Klepser TB. Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. Ann Pharmacother 2007;41:1018-22.
123. Messer PM, Hauffa BP, Olbricht T, Benker G, Kotulla P, Reinwein D. Antithyroid drug treatment of Graves' disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta Endocrinol (Copenh) 1990;123:311-6.
124. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999;33:1637-41.
125. Marks PW. Management of thromboembolism in pregnancy. Semin Perinatol 2007;31:227-31.
126. Suri V, Sawhney H, Vasishta K, Renuka T, Grover A. Pregnancy following cardiac valve replacement surgery. Int J Gynaecol Obstet 1999;64:239-46.
127. Vitale N, De Feo M, Cotrufo M. Anticoagulation for prosthetic heart valves during pregnancy: the importance of warfarin daily dose. Eur J Cardiothorac Surg 2002;22:656.